Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.
2
Table of Contents
1 Q1FY-23
HIGHLIGHTS
2
BUSINESS OVERVIEW
3CAPABILITIES
4 FINANCIALS
5
OUTLOOK
3
Q1FY-23 HIGHLIGHTS
Management Speak
SUCHETH DAVULURI
"We had a volatile quarter in which the GDS business saw a decline in revenue as the Prime segment performed below par and impacted EBITDA margins by around 300 bps. However, we witnessed an improved business mix as we saw GDS Specialty revenues from customer launches and pipeline products. We expect the shift in the portfolio to continue and deliver annual performance in line with our plans."
SAHARSH DAVULURI
"Although the CMS segment saw delays arising from technical complexities, we see promising growth ahead backed by addition of new projects. Our focus internally is on execution excellence and optimization of costs to ensure mitigation against external events. We remain optimistic that our overall business will grow in line with our long- term plans and reflect higher margins due to our focus on delivering challenging projects in line with our clients' technical needs. "
5
Attachments
Original Link
Original Document
Permalink
Disclaimer
Neuland Laboratories Ltd. published this content on 03 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2022 09:36:03 UTC.
Neuland Laboratories Limited is an India-based company, which is engaged in manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industryâs chemistry needs. The Company provide solutions across the full range of the pharmaceutical industryâs chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company operates through a single segment, manufacture of active pharmaceutical ingredients and allied services. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services.
NEULAND LABORATORIES LIMITED 
